Current research status of sitagliptin in treatment of type 2 diabetes mellitus

Sitagliptin as the earliest dipeptidyl peptidase-4 inhibitor marketed in China, when used alone or in combination with other drugs, can safely and effectively improve blood glucose, with little risk of hypoglycemia and weight gain among the patients. In addition to its hypoglycemic effect, sitagliptin also has the effects of cardiovascular protection and improvement of microvascular disease. This paper aims to review the current research status of sitagliptin in the treatment of type 2 diabetes mellitus. Key words: Sitagliptin; Diabetes mellitus; Blood glucose variability